These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 38402177

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL, Lip GYH, Feng Q, Fei Y, Tse YK, Wu MZ, Ren QW, Tse HF, Cheung BY, Yiu KH.
    Cardiovasc Diabetol; 2021 May 07; 20(1):100. PubMed ID: 33962654
    [Abstract] [Full Text] [Related]

  • 3. Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials.
    Sfairopoulos D, Liu T, Zhang N, Tse G, Bazoukis G, Letsas K, Goudis C, Milionis H, Vrettos A, Korantzopoulos P.
    Heart Fail Rev; 2023 Jul 07; 28(4):925-936. PubMed ID: 36282460
    [Abstract] [Full Text] [Related]

  • 4. Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials.
    Li D, Liu Y, Hidru TH, Yang X, Wang Y, Chen C, Li KHC, Tang Y, Wei Y, Tse G, Xia Y.
    Front Endocrinol (Lausanne); 2021 Jul 07; 12():619586. PubMed ID: 33815278
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Association between sodium-glucose cotransporter-2 inhibitors and risk of sudden cardiac death or ventricular arrhythmias: a meta-analysis of randomized controlled trials.
    Sfairopoulos D, Zhang N, Wang Y, Chen Z, Letsas KP, Tse G, Li G, Lip GYH, Liu T, Korantzopoulos P.
    Europace; 2022 Jan 04; 24(1):20-30. PubMed ID: 34333592
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials.
    Fernandes GC, Fernandes A, Cardoso R, Penalver J, Knijnik L, Mitrani RD, Myerburg RJ, Goldberger JJ.
    Heart Rhythm; 2021 Jul 04; 18(7):1098-1105. PubMed ID: 33757845
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
    Zelniker TA, Bonaca MP, Furtado RHM, Mosenzon O, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Budaj A, Kiss RG, Padilla F, Gause-Nilsson I, Langkilde AM, Raz I, Sabatine MS, Wiviott SD.
    Circulation; 2020 Apr 14; 141(15):1227-1234. PubMed ID: 31983236
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The effectiveness of SGLT2 inhibitor in the incidence of atrial fibrillation/atrial flutter in patients with type 2 diabetes mellitus/heart failure: a systematic review and meta-analysis.
    Wang M, Zhang Y, Wang Z, Liu D, Mao S, Liang B.
    J Thorac Dis; 2022 May 14; 14(5):1620-1637. PubMed ID: 35693625
    [Abstract] [Full Text] [Related]

  • 13. Increased risk of sudden and non-sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarction.
    Pedersen OD, Abildstrøm SZ, Ottesen MM, Rask-Madsen C, Bagger H, Køber L, Torp-Pedersen C, TRACE Study Investigators.
    Eur Heart J; 2006 Feb 14; 27(3):290-5. PubMed ID: 16267070
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Comparison of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials.
    Li W, Chen X, Xie X, Xu M, Xu L, Liu P, Luo B.
    J Cardiovasc Pharmacol; 2022 Mar 01; 79(3):281-288. PubMed ID: 34935705
    [Abstract] [Full Text] [Related]

  • 17. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
    Omar M, Jensen J, Ali M, Frederiksen PH, Kistorp C, Videbæk L, Poulsen MK, Tuxen CD, Möller S, Gustafsson F, Køber L, Schou M, Møller JE.
    JAMA Cardiol; 2021 Jul 01; 6(7):836-840. PubMed ID: 33404637
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.